B01: STROMAL CELL-NEUTROPHIL INTERACTIONS PROMOTE A PRO-TUMOR ENVIRONMENT IN MULTIPLE MYELOMA

B01: STROMAL CELL-NEUTROPHIL INTERACTIONS PROMOTE A PRO-TUMOR ENVIRONMENT IN MULTIPLE MYELOMA

Bibliographic Details
Main Authors:	M de Jong, C Fokkema, T van Heusden, N Papazian, S Tahri, Z Kellermayer, P Vermeulen, M van Duin, P van de Woestijne, A Broijl, P Sonneveld, T Cupedo
Format:	Article
Language:	English
Published:	Wiley 2022-04-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000829548.86376.1e

Similar Items

An IL-1β-driven neutrophil–stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma
by: de Jong, MME, et al.
Published: (2024)

B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS
by: R. Wester, et al.
Published: (2023-05-01)

V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma
by: Pim Mutsaers, et al.
Published: (2021-05-01)

B05 PLASMA CELL LEUKEMIA-LIKE STATUS HAS INDEPENDENT PROGNOSTIC VALUE IN THE CONTEXT OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM
by: D. Hofste op Bruinink, et al.
Published: (2023-05-01)

Neutrophilic hyperleukocytosis in the multiple myeloma onset
by: I. G. Rekhtina, et al.
Published: (2022-07-01)

Development of a Patient Centered Outcome Set for Patients With Multiple Myeloma to be Used in Clinical Practice
by: Simone Oerlemans, et al.
Published: (2020-06-01)

The Netherlands: Childbearing within the context of a "Poldermodel" society
by: Coen Van Duin, et al.
Published: (2008-07-01)

Editorial: Risk factors in multiple myeloma identified before and during treatment: are we ready to personalize treatment?
by: Mattia D’Agostino, et al.
Published: (2023-07-01)

P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)
by: Meral Beksac, et al.
Published: (2023-08-01)

P01.15. Multiple Myeloma, chemotherapy and curcumin
by: Panutich E, et al.
Published: (2012-06-01)

Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells
by: Zsolt Matula, et al.
Published: (2021-07-01)

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
by: Ruth Wester, et al.
Published: (2022-02-01)

Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
by: Mirian Brink, et al.
Published: (2021-11-01)

COVID-19 AND MYELOMA
by: H Ludwig, et al.
Published: (2022-04-01)

BEDRIJFSECONOMISCHE ASPECTEN VAN DE ARBEIDSMARKT
by: W. J. Van De Woestijne
Published: (1949-04-01)

BOEKBESPREKINGEN DE BETEKENIS VAN DE GROOTHANDEL IN IJZER EN STAAL VOOR DE
by: W. J. Van De Woestijne
Published: (1955-07-01)

ORGANISATIE EN VOORBEREIDING VAN BELEIDSBESLISSINGEN EN DE CONTROLE DAAROP
by: W. J. Van De Woestijne
Published: (1960-07-01)

NOTA VAN DE MINISTER VAN FINANCIËN INZAKE FISCALE WINSTBEPALING
by: W. J. Van De Woestijne
Published: (1951-04-01)

BOEKBESPREKING
by: W. J. Van De Woestijne
Published: (1948-12-01)

NAAR AANLEIDING VAN EEN AMSTERDAMSE DISSERTATIE1)
by: W. J. Van De Woestijne
Published: (1972-10-01)

BOEKBESPREKING KERNPROBLEMEN DER BEDRIJFSECONOMIE
by: W. J. Van De Woestijne
Published: (1966-06-01)

EFFICIËNTE DISTRIBUTIE VAN LEVENSMIDDELEN
by: W. J. Van De Woestijne
Published: (1954-05-01)

KOSTEN, PRIJZEN EN ASSORTIMENT
by: W. J. Van De Woestijne
Published: (1967-01-01)

BESCHOUWINGEN NAAR AANLEIDING VAN DE BEDRIJFSKOS TENSTATISTIEK VAN DE GROOTHANDEL IN KRUIDENIERS WAREN 1946
by: W. J. Van De Woestijne
Published: (1948-09-01)

BOEKBESPREKING
by: W. J. Van De Woestijne
Published: (1962-03-01)

NAAR EEN ALGEMENE WETENSCHAPPELIJKE BESTUDERING VAN ORGANISEREN, ORGANISATIE EN LEIDEN
by: W. J. Van De Woestijne
Published: (1954-12-01)

BEDRIJFSECONOMISCHE ASPECTEN VAN DE WERKCLASSIFICATIE
by: W. J. Van De Woestijne
Published: (1951-07-01)

DE MACHTSPOSITIE VAN DE MONOPOLIST
by: W. J. Van De Woestijne
Published: (1947-07-01)

BOEKBESPREKING
by: W. J. Van De Woestijne
Published: (1958-05-01)

KOSTENVERBIJZONDERING IN HANDELSBEDRIJVEN
by: W. J. Van De Woestijne
Published: (1954-03-01)

OVERHEIDSADMINISTRATIE EN PARTICULIERE EFFICIENTIE- BEWAKING
by: W. J. Van De Woestijne
Published: (1947-09-01)

ENKELE OPMERKINGEN OVER DE RECLAME ALS ELEMENT
by: W. J. Van De Woestijne
Published: (1951-04-01)

BMI1 regulates multiple myeloma-associated macrophage’s pro-myeloma functions
by: Danfeng Zhang, et al.
Published: (2021-05-01)

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression
by: Patricia Maiso, et al.
Published: (2021-05-01)

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
by: Ruth Wester, et al.
Published: (2020-08-01)

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands
by: Mirian Brink, et al.
Published: (2022-03-01)

Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells.
by: Thibaud André, et al.
Published: (2013-01-01)

P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY
by: F Schjesvold, et al.
Published: (2023-05-01)

Tumor-Associated Neutrophils in Cancer: Going Pro
by: Lingyun Wu, et al.
Published: (2019-04-01)

Algorithmic pricing
by: Adrianus Van Heusden
Published: (2023-07-01)